Nabriva Therapeutics to Present at the Jefferies Virtual Healthcare Conference

Rhea-AI Summary

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company focused on anti-infective agents, announced that CEO Ted Schroeder will present a company overview and business update at the Jefferies Virtual Healthcare Conference on June 3, at 2:30 p.m. ET. The presentation can be accessed via the 'Investors' section of Nabriva's website.

Nabriva is known for its FDA-approved XENLETA, the first pleuromutilin antibiotic for community-acquired bacterial pneumonia, and is developing CONTEPO for complicated urinary tract infections. It has an agreement with Merck to market SIVEXTRO.

DUBLIN, Ireland and KING OF PRUSSIA, Pa., May 21, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offer at Nabriva, will provide a company overview and business update at the Jefferies Virtual Healthcare Conference on Thursday, June 3, at 2:30 p.m. ET.

The presentation may be accessed by visiting the "Investors" section of the Company's website under the "Events and Presentations" tab at www.nabriva.com.

About Nabriva Therapeutics plc

Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA® (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP). Nabriva Therapeutics is also developing CONTEPO™ (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis. Nabriva entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO^® (tedizolid phosphate) in the United States and certain of its territories.

CONTACTS:

For Investors
Kim Anderson
Nabriva Therapeutics plc
IR@Nabriva.com

For Media
Andrea Greif
Ogilvy
andrea.greif@ogilvy.com
914-772-3027

FAQ

When will Nabriva Therapeutics present at the Jefferies Virtual Healthcare Conference?

Nabriva Therapeutics will present on June 3, 2021, at 2:30 p.m. ET.

Who is presenting for Nabriva Therapeutics at the conference?

Ted Schroeder, the Chief Executive Officer of Nabriva, will provide the presentation.

How can I access the Nabriva Therapeutics presentation?

The presentation can be accessed on the Nabriva website under the 'Investors' section and the 'Events and Presentations' tab.

What is the significance of XENLETA for Nabriva Therapeutics?

XENLETA is the first systemic pleuromutilin antibiotic approved by the FDA for community-acquired bacterial pneumonia.

What is CONTEPO being developed for by Nabriva Therapeutics?

CONTEPO is being developed as a potential first-in-class epoxide antibiotic for complicated urinary tract infections.